nodes	percent_of_prediction	percent_of_DWPC	metapath
Neostigmine—ABCB1—Vismodegib—skin cancer	0.296	0.557	CbGbCtD
Neostigmine—ABCB1—Dactinomycin—skin cancer	0.155	0.292	CbGbCtD
Neostigmine—ABCB1—Docetaxel—skin cancer	0.0802	0.151	CbGbCtD
Neostigmine—Procedural pain—Imiquimod—skin cancer	0.0226	0.0483	CcSEcCtD
Neostigmine—Paralysis—Vemurafenib—skin cancer	0.0109	0.0233	CcSEcCtD
Neostigmine—Abnormal behaviour—Temozolomide—skin cancer	0.0104	0.0222	CcSEcCtD
Neostigmine—Pharyngolaryngeal pain—Imiquimod—skin cancer	0.00959	0.0205	CcSEcCtD
Neostigmine—Laryngeal pain—Imiquimod—skin cancer	0.00949	0.0203	CcSEcCtD
Neostigmine—Slurred speech—Fluorouracil—skin cancer	0.00799	0.0171	CcSEcCtD
Neostigmine—Cardiovascular disorder—Imiquimod—skin cancer	0.00737	0.0157	CcSEcCtD
Neostigmine—Lacrimation—Fluorouracil—skin cancer	0.00608	0.013	CcSEcCtD
Neostigmine—Connective tissue disorder—Vismodegib—skin cancer	0.00606	0.0129	CcSEcCtD
Neostigmine—Chest tightness—Docetaxel—skin cancer	0.0055	0.0117	CcSEcCtD
Neostigmine—Muscle spasms—Vismodegib—skin cancer	0.00516	0.011	CcSEcCtD
Neostigmine—Nystagmus—Fluorouracil—skin cancer	0.005	0.0107	CcSEcCtD
Neostigmine—Arthralgia—Vismodegib—skin cancer	0.00457	0.00976	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Vismodegib—skin cancer	0.00454	0.00969	CcSEcCtD
Neostigmine—Wheezing—Bleomycin—skin cancer	0.00447	0.00953	CcSEcCtD
Neostigmine—Lacrimation—Docetaxel—skin cancer	0.00439	0.00936	CcSEcCtD
Neostigmine—Nervous system disorder—Vismodegib—skin cancer	0.0043	0.00917	CcSEcCtD
Neostigmine—Skin disorder—Vismodegib—skin cancer	0.00426	0.00908	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Vismodegib—skin cancer	0.00399	0.00852	CcSEcCtD
Neostigmine—Sweating increased—Imiquimod—skin cancer	0.00396	0.00844	CcSEcCtD
Neostigmine—Lacrimation increased—Fluorouracil—skin cancer	0.00388	0.00827	CcSEcCtD
Neostigmine—Pharyngolaryngeal pain—Docetaxel—skin cancer	0.00382	0.00815	CcSEcCtD
Neostigmine—Laryngeal pain—Docetaxel—skin cancer	0.00378	0.00807	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Vismodegib—skin cancer	0.00378	0.00807	CcSEcCtD
Neostigmine—Dysarthria—Fluorouracil—skin cancer	0.00378	0.00806	CcSEcCtD
Neostigmine—Urinary incontinence—Temozolomide—skin cancer	0.00375	0.00799	CcSEcCtD
Neostigmine—Connective tissue disorder—Vemurafenib—skin cancer	0.00374	0.00799	CcSEcCtD
Neostigmine—Gastrointestinal pain—Vismodegib—skin cancer	0.00358	0.00765	CcSEcCtD
Neostigmine—Abdominal pain—Vismodegib—skin cancer	0.00346	0.00739	CcSEcCtD
Neostigmine—Mediastinal disorder—Vemurafenib—skin cancer	0.00343	0.00733	CcSEcCtD
Neostigmine—Coma—Fluorouracil—skin cancer	0.00327	0.00697	CcSEcCtD
Neostigmine—Urinary tract disorder—Imiquimod—skin cancer	0.00321	0.00685	CcSEcCtD
Neostigmine—Connective tissue disorder—Imiquimod—skin cancer	0.00319	0.00682	CcSEcCtD
Neostigmine—Urethral disorder—Imiquimod—skin cancer	0.00319	0.0068	CcSEcCtD
Neostigmine—Asthenia—Vismodegib—skin cancer	0.00314	0.00671	CcSEcCtD
Neostigmine—Pruritus—Vismodegib—skin cancer	0.0031	0.00662	CcSEcCtD
Neostigmine—Flushing—Imiquimod—skin cancer	0.00302	0.00644	CcSEcCtD
Neostigmine—Diarrhoea—Vismodegib—skin cancer	0.003	0.0064	CcSEcCtD
Neostigmine—Mediastinal disorder—Imiquimod—skin cancer	0.00293	0.00625	CcSEcCtD
Neostigmine—Chest discomfort—Docetaxel—skin cancer	0.00291	0.00622	CcSEcCtD
Neostigmine—Arrhythmia—Imiquimod—skin cancer	0.0029	0.0062	CcSEcCtD
Neostigmine—Mental disorder—Imiquimod—skin cancer	0.00285	0.00608	CcSEcCtD
Neostigmine—Bronchospasm—Bleomycin—skin cancer	0.00284	0.00605	CcSEcCtD
Neostigmine—Arthralgia—Vemurafenib—skin cancer	0.00282	0.00603	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.0028	0.00599	CcSEcCtD
Neostigmine—Lacrimation increased—Docetaxel—skin cancer	0.0028	0.00597	CcSEcCtD
Neostigmine—Vomiting—Vismodegib—skin cancer	0.00279	0.00595	CcSEcCtD
Neostigmine—Rash—Vismodegib—skin cancer	0.00276	0.0059	CcSEcCtD
Neostigmine—Dermatitis—Vismodegib—skin cancer	0.00276	0.00589	CcSEcCtD
Neostigmine—Anaphylactic shock—Vemurafenib—skin cancer	0.00271	0.00578	CcSEcCtD
Neostigmine—Nervous system disorder—Vemurafenib—skin cancer	0.00266	0.00567	CcSEcCtD
Neostigmine—Skin disorder—Vemurafenib—skin cancer	0.00263	0.00561	CcSEcCtD
Neostigmine—Nausea—Vismodegib—skin cancer	0.0026	0.00555	CcSEcCtD
Neostigmine—Agitation—Imiquimod—skin cancer	0.0026	0.00555	CcSEcCtD
Neostigmine—Osteoarthritis—Fluorouracil—skin cancer	0.00259	0.00554	CcSEcCtD
Neostigmine—Syncope—Imiquimod—skin cancer	0.00254	0.00541	CcSEcCtD
Neostigmine—Hypotension—Vemurafenib—skin cancer	0.00253	0.0054	CcSEcCtD
Neostigmine—Loss of consciousness—Imiquimod—skin cancer	0.00249	0.00531	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.00247	0.00526	CcSEcCtD
Neostigmine—Cardiac arrest—Fluorouracil—skin cancer	0.00247	0.00526	CcSEcCtD
Neostigmine—Convulsion—Imiquimod—skin cancer	0.00245	0.00523	CcSEcCtD
Neostigmine—Arthralgia—Imiquimod—skin cancer	0.00241	0.00514	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.00239	0.0051	CcSEcCtD
Neostigmine—Sweating increased—Temozolomide—skin cancer	0.00237	0.00506	CcSEcCtD
Neostigmine—Dry mouth—Imiquimod—skin cancer	0.00236	0.00503	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Vemurafenib—skin cancer	0.00234	0.00499	CcSEcCtD
Neostigmine—Shock—Imiquimod—skin cancer	0.00227	0.00485	CcSEcCtD
Neostigmine—Nervous system disorder—Imiquimod—skin cancer	0.00226	0.00483	CcSEcCtD
Neostigmine—Tachycardia—Imiquimod—skin cancer	0.00225	0.00481	CcSEcCtD
Neostigmine—Pollakiuria—Temozolomide—skin cancer	0.00225	0.0048	CcSEcCtD
Neostigmine—Skin disorder—Imiquimod—skin cancer	0.00224	0.00479	CcSEcCtD
Neostigmine—Hyperhidrosis—Imiquimod—skin cancer	0.00223	0.00476	CcSEcCtD
Neostigmine—Flushing—Bleomycin—skin cancer	0.00214	0.00457	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Imiquimod—skin cancer	0.0021	0.00449	CcSEcCtD
Neostigmine—Insomnia—Imiquimod—skin cancer	0.00209	0.00446	CcSEcCtD
Neostigmine—Dyspnoea—Imiquimod—skin cancer	0.00206	0.00439	CcSEcCtD
Neostigmine—Somnolence—Imiquimod—skin cancer	0.00205	0.00438	CcSEcCtD
Neostigmine—Flushing—Dactinomycin—skin cancer	0.002	0.00426	CcSEcCtD
Neostigmine—Hypersensitivity—Vemurafenib—skin cancer	0.00199	0.00426	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Imiquimod—skin cancer	0.00199	0.00425	CcSEcCtD
Neostigmine—Asthenia—Vemurafenib—skin cancer	0.00194	0.00415	CcSEcCtD
Neostigmine—Urinary tract disorder—Temozolomide—skin cancer	0.00192	0.0041	CcSEcCtD
Neostigmine—Pruritus—Vemurafenib—skin cancer	0.00192	0.00409	CcSEcCtD
Neostigmine—Connective tissue disorder—Temozolomide—skin cancer	0.00191	0.00408	CcSEcCtD
Neostigmine—Urethral disorder—Temozolomide—skin cancer	0.00191	0.00407	CcSEcCtD
Neostigmine—Gastrointestinal pain—Imiquimod—skin cancer	0.00189	0.00403	CcSEcCtD
Neostigmine—Diarrhoea—Vemurafenib—skin cancer	0.00185	0.00395	CcSEcCtD
Neostigmine—Urticaria—Imiquimod—skin cancer	0.00183	0.00391	CcSEcCtD
Neostigmine—Abdominal pain—Imiquimod—skin cancer	0.00183	0.0039	CcSEcCtD
Neostigmine—Flushing—Temozolomide—skin cancer	0.00181	0.00386	CcSEcCtD
Neostigmine—Dizziness—Vemurafenib—skin cancer	0.00179	0.00382	CcSEcCtD
Neostigmine—Mediastinal disorder—Temozolomide—skin cancer	0.00176	0.00375	CcSEcCtD
Neostigmine—Vomiting—Vemurafenib—skin cancer	0.00172	0.00367	CcSEcCtD
Neostigmine—Rash—Vemurafenib—skin cancer	0.00171	0.00364	CcSEcCtD
Neostigmine—Mental disorder—Temozolomide—skin cancer	0.00171	0.00364	CcSEcCtD
Neostigmine—Dermatitis—Vemurafenib—skin cancer	0.00171	0.00364	CcSEcCtD
Neostigmine—Hypersensitivity—Imiquimod—skin cancer	0.0017	0.00363	CcSEcCtD
Neostigmine—Headache—Vemurafenib—skin cancer	0.0017	0.00362	CcSEcCtD
Neostigmine—Cramp muscle—Docetaxel—skin cancer	0.00169	0.0036	CcSEcCtD
Neostigmine—Asthenia—Imiquimod—skin cancer	0.00166	0.00354	CcSEcCtD
Neostigmine—Anaphylactic shock—Bleomycin—skin cancer	0.00164	0.0035	CcSEcCtD
Neostigmine—Pruritus—Imiquimod—skin cancer	0.00163	0.00349	CcSEcCtD
Neostigmine—Nausea—Vemurafenib—skin cancer	0.00161	0.00343	CcSEcCtD
Neostigmine—Arrhythmia—Fluorouracil—skin cancer	0.0016	0.00342	CcSEcCtD
Neostigmine—Bronchospasm—Docetaxel—skin cancer	0.00159	0.0034	CcSEcCtD
Neostigmine—Diarrhoea—Imiquimod—skin cancer	0.00158	0.00337	CcSEcCtD
Neostigmine—Agitation—Temozolomide—skin cancer	0.00156	0.00332	CcSEcCtD
Neostigmine—Hypotension—Bleomycin—skin cancer	0.00153	0.00327	CcSEcCtD
Neostigmine—Dizziness—Imiquimod—skin cancer	0.00153	0.00326	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Bleomycin—skin cancer	0.00149	0.00319	CcSEcCtD
Neostigmine—Convulsion—Temozolomide—skin cancer	0.00147	0.00313	CcSEcCtD
Neostigmine—Vomiting—Imiquimod—skin cancer	0.00147	0.00313	CcSEcCtD
Neostigmine—Dyspnoea—Bleomycin—skin cancer	0.00146	0.00312	CcSEcCtD
Neostigmine—Rash—Imiquimod—skin cancer	0.00146	0.00311	CcSEcCtD
Neostigmine—Dermatitis—Imiquimod—skin cancer	0.00145	0.0031	CcSEcCtD
Neostigmine—Headache—Imiquimod—skin cancer	0.00145	0.00309	CcSEcCtD
Neostigmine—Arthralgia—Temozolomide—skin cancer	0.00144	0.00308	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.00143	0.00306	CcSEcCtD
Neostigmine—Dry mouth—Temozolomide—skin cancer	0.00141	0.00301	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.00139	0.00297	CcSEcCtD
Neostigmine—Anaphylactic shock—Temozolomide—skin cancer	0.00138	0.00295	CcSEcCtD
Neostigmine—Nausea—Imiquimod—skin cancer	0.00137	0.00293	CcSEcCtD
Neostigmine—Nervous system disorder—Temozolomide—skin cancer	0.00136	0.0029	CcSEcCtD
Neostigmine—Convulsion—Fluorouracil—skin cancer	0.00135	0.00289	CcSEcCtD
Neostigmine—Skin disorder—Temozolomide—skin cancer	0.00134	0.00287	CcSEcCtD
Neostigmine—Hyperhidrosis—Temozolomide—skin cancer	0.00134	0.00285	CcSEcCtD
Neostigmine—Urticaria—Bleomycin—skin cancer	0.0013	0.00278	CcSEcCtD
Neostigmine—Urinary tract disorder—Docetaxel—skin cancer	0.00128	0.00273	CcSEcCtD
Neostigmine—Anaphylactic shock—Fluorouracil—skin cancer	0.00127	0.00272	CcSEcCtD
Neostigmine—Connective tissue disorder—Docetaxel—skin cancer	0.00127	0.00272	CcSEcCtD
Neostigmine—Urethral disorder—Docetaxel—skin cancer	0.00127	0.00271	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Temozolomide—skin cancer	0.00126	0.00269	CcSEcCtD
Neostigmine—Insomnia—Temozolomide—skin cancer	0.00125	0.00267	CcSEcCtD
Neostigmine—Gastrointestinal pain—Dactinomycin—skin cancer	0.00125	0.00267	CcSEcCtD
Neostigmine—Nervous system disorder—Fluorouracil—skin cancer	0.00125	0.00267	CcSEcCtD
Neostigmine—Tachycardia—Fluorouracil—skin cancer	0.00124	0.00266	CcSEcCtD
Neostigmine—Dyspnoea—Temozolomide—skin cancer	0.00123	0.00263	CcSEcCtD
Neostigmine—Somnolence—Temozolomide—skin cancer	0.00123	0.00262	CcSEcCtD
Neostigmine—Abdominal pain—Dactinomycin—skin cancer	0.00121	0.00258	CcSEcCtD
Neostigmine—Hypersensitivity—Bleomycin—skin cancer	0.00121	0.00258	CcSEcCtD
Neostigmine—Flushing—Docetaxel—skin cancer	0.0012	0.00257	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Temozolomide—skin cancer	0.00119	0.00255	CcSEcCtD
Neostigmine—Hypotension—Fluorouracil—skin cancer	0.00119	0.00254	CcSEcCtD
Neostigmine—Asthenia—Bleomycin—skin cancer	0.00118	0.00251	CcSEcCtD
Neostigmine—Mediastinal disorder—Docetaxel—skin cancer	0.00117	0.00249	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.00116	0.00248	CcSEcCtD
Neostigmine—Pruritus—Bleomycin—skin cancer	0.00116	0.00248	CcSEcCtD
Neostigmine—Arrhythmia—Docetaxel—skin cancer	0.00116	0.00247	CcSEcCtD
Neostigmine—Insomnia—Fluorouracil—skin cancer	0.00115	0.00246	CcSEcCtD
Neostigmine—Dyspnoea—Fluorouracil—skin cancer	0.00114	0.00243	CcSEcCtD
Neostigmine—Mental disorder—Docetaxel—skin cancer	0.00113	0.00242	CcSEcCtD
Neostigmine—Somnolence—Fluorouracil—skin cancer	0.00113	0.00242	CcSEcCtD
Neostigmine—Gastrointestinal pain—Temozolomide—skin cancer	0.00113	0.00241	CcSEcCtD
Neostigmine—Hypersensitivity—Dactinomycin—skin cancer	0.00113	0.00241	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Fluorouracil—skin cancer	0.0011	0.00235	CcSEcCtD
Neostigmine—Urticaria—Temozolomide—skin cancer	0.0011	0.00235	CcSEcCtD
Neostigmine—Asthenia—Dactinomycin—skin cancer	0.0011	0.00234	CcSEcCtD
Neostigmine—Abdominal pain—Temozolomide—skin cancer	0.00109	0.00233	CcSEcCtD
Neostigmine—Muscle spasms—Docetaxel—skin cancer	0.00108	0.00231	CcSEcCtD
Neostigmine—Diarrhoea—Dactinomycin—skin cancer	0.00105	0.00223	CcSEcCtD
Neostigmine—Vomiting—Bleomycin—skin cancer	0.00104	0.00223	CcSEcCtD
Neostigmine—Rash—Bleomycin—skin cancer	0.00103	0.00221	CcSEcCtD
Neostigmine—Dermatitis—Bleomycin—skin cancer	0.00103	0.00221	CcSEcCtD
Neostigmine—Hypersensitivity—Temozolomide—skin cancer	0.00102	0.00218	CcSEcCtD
Neostigmine—Urticaria—Fluorouracil—skin cancer	0.00101	0.00216	CcSEcCtD
Neostigmine—Syncope—Docetaxel—skin cancer	0.00101	0.00216	CcSEcCtD
Neostigmine—Asthenia—Temozolomide—skin cancer	0.000993	0.00212	CcSEcCtD
Neostigmine—Loss of consciousness—Docetaxel—skin cancer	0.000991	0.00211	CcSEcCtD
Neostigmine—Pruritus—Temozolomide—skin cancer	0.000979	0.00209	CcSEcCtD
Neostigmine—Convulsion—Docetaxel—skin cancer	0.000977	0.00208	CcSEcCtD
Neostigmine—Nausea—Bleomycin—skin cancer	0.000974	0.00208	CcSEcCtD
Neostigmine—Vomiting—Dactinomycin—skin cancer	0.000973	0.00208	CcSEcCtD
Neostigmine—Rash—Dactinomycin—skin cancer	0.000965	0.00206	CcSEcCtD
Neostigmine—Arthralgia—Docetaxel—skin cancer	0.00096	0.00205	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000953	0.00203	CcSEcCtD
Neostigmine—Diarrhoea—Temozolomide—skin cancer	0.000947	0.00202	CcSEcCtD
Neostigmine—Hypersensitivity—Fluorouracil—skin cancer	0.000939	0.002	CcSEcCtD
Neostigmine—Dry mouth—Docetaxel—skin cancer	0.000939	0.002	CcSEcCtD
Neostigmine—Anaphylactic shock—Docetaxel—skin cancer	0.00092	0.00196	CcSEcCtD
Neostigmine—Dizziness—Temozolomide—skin cancer	0.000915	0.00195	CcSEcCtD
Neostigmine—Nausea—Dactinomycin—skin cancer	0.000909	0.00194	CcSEcCtD
Neostigmine—Shock—Docetaxel—skin cancer	0.000905	0.00193	CcSEcCtD
Neostigmine—Nervous system disorder—Docetaxel—skin cancer	0.000902	0.00193	CcSEcCtD
Neostigmine—Pruritus—Fluorouracil—skin cancer	0.000902	0.00192	CcSEcCtD
Neostigmine—Tachycardia—Docetaxel—skin cancer	0.000898	0.00192	CcSEcCtD
Neostigmine—Skin disorder—Docetaxel—skin cancer	0.000894	0.00191	CcSEcCtD
Neostigmine—Vomiting—Temozolomide—skin cancer	0.00088	0.00188	CcSEcCtD
Neostigmine—Rash—Temozolomide—skin cancer	0.000872	0.00186	CcSEcCtD
Neostigmine—Diarrhoea—Fluorouracil—skin cancer	0.000872	0.00186	CcSEcCtD
Neostigmine—Dermatitis—Temozolomide—skin cancer	0.000872	0.00186	CcSEcCtD
Neostigmine—Headache—Temozolomide—skin cancer	0.000867	0.00185	CcSEcCtD
Neostigmine—Hypotension—Docetaxel—skin cancer	0.00086	0.00183	CcSEcCtD
Neostigmine—Dizziness—Fluorouracil—skin cancer	0.000843	0.0018	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000838	0.00179	CcSEcCtD
Neostigmine—Insomnia—Docetaxel—skin cancer	0.000832	0.00178	CcSEcCtD
Neostigmine—Nausea—Temozolomide—skin cancer	0.000822	0.00175	CcSEcCtD
Neostigmine—Dyspnoea—Docetaxel—skin cancer	0.00082	0.00175	CcSEcCtD
Neostigmine—Somnolence—Docetaxel—skin cancer	0.000818	0.00175	CcSEcCtD
Neostigmine—Vomiting—Fluorouracil—skin cancer	0.000811	0.00173	CcSEcCtD
Neostigmine—Rash—Fluorouracil—skin cancer	0.000804	0.00172	CcSEcCtD
Neostigmine—Dermatitis—Fluorouracil—skin cancer	0.000803	0.00171	CcSEcCtD
Neostigmine—Headache—Fluorouracil—skin cancer	0.000799	0.0017	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Docetaxel—skin cancer	0.000794	0.0017	CcSEcCtD
Neostigmine—Nausea—Fluorouracil—skin cancer	0.000757	0.00162	CcSEcCtD
Neostigmine—Gastrointestinal pain—Docetaxel—skin cancer	0.000752	0.00161	CcSEcCtD
Neostigmine—Abdominal pain—Docetaxel—skin cancer	0.000727	0.00155	CcSEcCtD
Neostigmine—Hypersensitivity—Docetaxel—skin cancer	0.000678	0.00145	CcSEcCtD
Neostigmine—Asthenia—Docetaxel—skin cancer	0.00066	0.00141	CcSEcCtD
Neostigmine—Pruritus—Docetaxel—skin cancer	0.000651	0.00139	CcSEcCtD
Neostigmine—Diarrhoea—Docetaxel—skin cancer	0.00063	0.00134	CcSEcCtD
Neostigmine—Dizziness—Docetaxel—skin cancer	0.000609	0.0013	CcSEcCtD
Neostigmine—Vomiting—Docetaxel—skin cancer	0.000585	0.00125	CcSEcCtD
Neostigmine—Rash—Docetaxel—skin cancer	0.00058	0.00124	CcSEcCtD
Neostigmine—Dermatitis—Docetaxel—skin cancer	0.00058	0.00124	CcSEcCtD
Neostigmine—Headache—Docetaxel—skin cancer	0.000576	0.00123	CcSEcCtD
Neostigmine—Nausea—Docetaxel—skin cancer	0.000547	0.00117	CcSEcCtD
